Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...
Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...
The new data presented by Novartis at ECTRIMS 2022 highlighted the safety and efficacy of Kesimpta and supported its use as an early intervention treatment option, as well as demonstrating high ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback